Lecalcif

Colecalciferol, the active ingredient in Lecalcif, is a Vitamin D3 (secosteroid) presented as an oral supplement for oral use. It treats vitamin D deficiency and supports bone health in individuals at risk of osteomalacia, rickets, or osteoporosis.

GNH USA supplies Lecalcif as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lecalcif, a vitamin D3 preparation, is used to address conditions linked to insufficient vitamin D and impaired bone mineralisation. - Vitamin D deficiency: restores normal serum 25‑hydroxyvitamin D levels and improves calcium balance. - Osteomalacia / rickets: promotes bone mineralisation and reduces bone pain in children and adults. - Osteoporosis: supports bone health and may help reduce fracture risk when combined with other osteoporosis therapies.

Adverse reactions may occur with any vitamin D supplement. Most are mild and reversible.

Common Side Effects: - Hypercalcaemia: elevated blood calcium levels causing fatigue or nausea. - Nausea or vomiting. - Constipation. - Headache. - Dry mouth. - Muscle weakness.

Serious or Rare Side Effects: - Severe hypercalcaemia leading to cardiac arrhythmia. - Nephrolithiasis (kidney stones). - Acute pancreatitis. - Anaphylactic reaction or severe skin rash. - Hypercalciuria causing renal impairment. - Hyperphosphataemia.

Before initiating therapy, consider patient‑specific factors and monitor relevant parameters. - Serum calcium assessment: check baseline calcium to avoid hypercalcaemia. - Renal function monitoring: evaluate kidney health, especially in patients with a history of stones. - Concomitant calcium intake: avoid excessive calcium supplementation without medical guidance. - Underlying granulomatous disease: use with caution in sarcoidosis or tuberculosis. - Pregnancy and lactation: safety not fully established; weigh benefits against potential risks. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Colecalciferol may alter the pharmacokinetics or pharmacodynamics of several medicines.

Major Interactions (Avoid): - Thiazide diuretics: can increase risk of hypercalcaemia. - Vitamin A excess: synergistic hypercalcaemia risk. - Calcium‑containing antacids: may cause excessive calcium levels.

Moderate Interactions (Monitor Closely): - Orlistat: may reduce vitamin D absorption; separate dosing by at least 2 hours. - Anticonvulsants (e.g., phenytoin, phenobarbital): increase vitamin D metabolism, possibly reducing efficacy. - Glucocorticoids: may diminish vitamin D activity, requiring monitoring. - Bile acid sequestrants: can lower absorption of fat‑soluble vitamins. - Cholestyramine: may decrease vitamin D bioavailability.